β-1a干扰素治疗多发性硬化症的临床观察

目的 探讨β-1a干扰素治疗多发性硬化症的临床疗效与安全性.方法 54例入选病例随机分为β-1a干扰素治疗组或安慰剂组,治疗组每次皮下注射β-1a干扰素20 mg,每周3次,维持2年.用药患者在最初6个月中每月作1次神经系统检查,之后每3个月查1次.所有病人每年做2次MRI检查,并对所获数据进行统计学分析.结果 β-1a干扰素治疗的病人第1年和第2年的复发率比安慰剂组有明显降低(治疗组平均每人1.62次,安慰剂组2.78次);复发危险性减低27%;首次复发时间推迟3个月(20mg组),并且无复发的病人比例大大提高(P＜0.05).治疗组病人注射部位的局部反应很常见,但大多轻微.结论 在降低复发率、减轻残障程度和改善MRI病灶等方面,用皮下β-1a干扰素治疗多发性硬化疗效确切,不良反应小.     

干扰素-β治疗复发-缓解型多发性硬化系统评价

目的评价干扰素-β(IFN-β)治疗复发-缓解型多发性硬化的有效性和安全性。方法检索Cochrane临床对照试验中心注册库、美国国立医学图书馆、荷兰医学文摘、CINAHL、LILACS、PEDRO、中国生物医学文献数据库、临床试验注册中心和世界卫生组织国际临床试验注册平台(检索截止时间:2014年6月);并通过阅读相关论文参考文献,联系参与IFN-β治疗多发性硬化临床试验的研究者和企业,进一步获取研究信息或未发表的数据。由两名评价人员独立筛选研究、提取研究信息和数据、评价偏倚风险。应用Review Manager软件(Version 5.3.3)进行Meta分析,GRADEpro软件评价研究设计和实施过程中的局限性(偏倚风险)、结果的不一致性和不精确性、证据的间接性和发表偏倚对主体证据质量的影响。结果共检索相关文献576篇,阅读标题和摘要后初步筛选出26项研究;进一步阅读全文后纳入5项研究(共2129例复发-缓解型多发性硬化患者:高剂量IFN-β组1076例、安慰剂组1053例)。所有纳入的研究均为IFN-β单药治疗且随访时间≥1年的随机双盲安慰剂对照平行临床试验。大多数研究存在方法学局限性,主要缺陷为随访偏倚风险较高,且数据分析未使用意向治疗原则,仅919例受试者(43.17%)的数据可用于分析随访2年时的主要结局。Meta分析显示,IFN-β可轻微减少随访2年时复发病例数(RR=0.810,95%CI:0.740~0.890;P=0.000)和残疾进展病例数(RR=0.700,95%CI:0.550~0.880;P=0.002);敏感性分析(最差情况的演示分析)显示,IFN-β治疗无效(RR=1.110,95%CI:0.730~1.680,P=0.620;RR=1.310,95%CI:0.600~2.890,P=0.500)。共1581例患者(74.26%)的数据可用于分析随访1年时至少复发1次的病例数(RR=0.740,95%CI:0.590~0.930;P=0.010),绝对危险降低率为13.24%,需治疗的病例数为8例,表明需要治疗8例患者才可防止1例在第1年内复发。但在年复发率方面,IFN-β治疗无效。IFN-β常导致注射部位局部反应、寒颤、发热、肌肉疼痛、流感样症状、头痛、血清丙氨酸转氨酶和天冬氨酸转氨酶水平升高等不良事件,但并不增加外周血淋巴细胞和中性粒细胞减少、抑郁、自杀行为或自杀观念的发生。结论高质量证据显示,IFN-β治疗复发-缓解型多发性硬化可轻微降低第1年内的复发病例数,但超过1年的疗效尚不能确定。目前尚无足够证据证明IFN-β在减少残疾进展病例数方面的疗效,尚待高质量的随机对照临床试验评价其长期有效性。     

定期糖皮质激素治疗复发-缓解型多发性硬化临床试验

<正> 2009年第6期Lancet Neurology发表了复发-缓解型多发性硬化(RRMS)患者口服甲强龙作为干扰素β1a添加治疗的北欧研究(NORdic trial of oral methylprednisoloneas add-on therapy to interferon beta-1a for treatment ofrelapsing-remitting multiple sclerosis,NORMIMS study)结果。该研究采用双盲评价法,对使用干扰素治疗期间仍有复发的RRMS患者添加口服大剂量甲强龙或安慰剂,经96周的治疗发现,定期添加大剂量糖皮质激素(以下简称激素)组患者复发率显著低于安慰剂组,而严重不良反应并     

干扰素-β-1b治疗多发性硬化的疗效及不良反应观察

目的探讨干扰素-β-1b(IFN-β-1b)用于治疗中国多发性硬化(MS)患者的疗效及不良反应。方法对12例确诊的复发缓解型MS(RRMS)患者给予IFN-β-1b治疗,并于治疗后第4、8、12、24周随访。通过观察患者扩展的功能缺损状况量表(EDSS)评分、头MRI T2加权像病灶数量及Gd-DTPA强化病灶数量、体积的演变,综合评价IFN-β-1b治疗MS的疗效,并通过分析血常规、肝肾功能等检测指标及不良反应综合评价该药物的不良反应。结果 (1)12例患者治疗前与治疗后24周EDSS评分比较差异无统计学意义(P>0.05);(2)治疗前6个月疾病复发率为33.33%(4/12),治疗后24周内复发率41.67%(5/12),两者比较差异无统计学意义(P>0.05);(3)与治疗前相比,治疗后第12周及第24周时MRI检查发现T2病灶数量、Gd-DTPA强化病灶数量及体积均明显减少(P<0.05)。(4)治疗后第24周血清尿酸、肌酐水平〔分别为(66.64±16.15)(、295.48±165.36)μmol/L〕与治疗前〔分别为(69.07±14.70)(、319.86±113.61)μmol/L〕相比明显降低(P<0.01),血尿素氮、肝功能、血常规等血液指标与治疗前相比差异无统计学意义(P>0.05)。(5)所有患者分别出现不同程度的局部注射部位红肿、头疼、肌肉关节疼痛、发热等不良反应。结论 IFN-β-1b用于治疗MS患者在24周内可以改善影像学改变情况,但不能明显改善疾病复发和临床神经功能障碍程度;IFN-β-1b的常见不良反应为注射局部红肿、头疼、肌肉关节疼痛、发热等。     

干扰素-β治疗多发性硬化

主要临床研究均证实干扰素-β(IFN-β)治疗复发-缓解型多发性硬化(RRMS)疗效肯定,且在一定剂量范围内疗效与剂量、频次呈正相关,IFN-β已经成为治疗RRMS的首选药物之一。IFN-β常见副作用包括流感样症状和注射部位反应等,在应用IFN-β早期尤为明显;大多数副作用比较轻微,严重的或患者不能耐受的不良反应少见。IFN-β中和抗体阳性可能影响疗效,但尚无统一结论。此文就不同类型IFN-β的异同及其治疗MS疗效判定标准、治疗时机和治疗剂量等作一综述。     

干扰素-β对实验性自身免疫性神经炎治疗作用的组织病理学和免疫学研究

目的:探讨干扰素β-(interferonβ-,IFNβ-)对实验性自身免疫性神经炎(experimentalautoimmuneneuritis,EAN)的治疗作用。方法:从牛坐骨神经提取髓鞘碱性蛋白(myelinbasicprotein,MBP)制备免疫原注射入豚鼠双后足垫诱导EAN模型。将90只健康、成年、雄性豚鼠随机分为正常对照组、IFN-β治疗EAN组、磷酸盐缓冲生理盐水(phosphatebuffedsaline,PBS)治疗EAN组,每组30只。免疫后第12天给予IFN-β或PBS腹腔注射,分别在治疗后7和14d对各组大鼠进行组织病理学和免疫学指标的检测。结果:与PBS治疗组相比,接受IFN-β治疗的豚鼠临床评分较低,坐骨神经干脱髓鞘程度轻,炎细胞浸润减少;脾脏单个核细胞IFN-γ、TNF-α的分泌量减少,IL-4、TGF-β的分泌增多。结论:IFN-β能改善EAN临床症状,促进疾病恢复,具有一定的治疗作用。     

β-干扰素治疗继发进展型多发性硬化临床疗效的荟萃分析

目的系统评价β-干扰素(interferon-β,IFN-β)维持治疗继发进展型多发性硬化的临床疗效。方法采用Cochrane系统评价方法,通过电子检索MEDLINE、EMbas、CBMdisc、Cochrane LibraryI、SI和美国临床试验登记中心等的数据库文献。评价纳入文献的方法学质量后,采用RevMan 4.2.10软件对提取的数据进行分析。结果共纳入4个RCTs研究。IFN-β治疗组与对照组比较,EDSS评分显示的2年疾病进展率差异有统计学意义(P=0.02<0.05,OR=0.82,95%CI=0.70~0.97),EDSS评分显示的3年疾病进展率差异无统计学意义(P=0.29>0.05,OR=0.85,95%CI=0.62~1.15),平均年复发率差异有统计学意义(P<0.00001,OR=0.48,95%CI=0.41~0.57)。结论IFN-β维持治疗继发进展型多发性硬化能降低EDSS评分显示的2年疾病进展率,不能降低EDSS评分显示的3年疾病进展率,可明显降低平均年复发率。     

甲基强的松龙联合β-干扰素治疗多发性硬化疗效观察

目的观察甲基强的松龙联合β-干扰素治疗多发性硬化(MS)急性期的临床疗效。方法对50例临床确诊为MS急性期的患者随机分为甲基强的龙组和甲基强的龙+β-干扰素组(联合治疗组)。2组患者治疗前后均进行Kurtzke伤残等级疗效评定及临床疗效评定。结果联合治疗组的显效率及治疗后Kurtzke伤残等级评分(EDSS)与甲基强的松龙组比较,差异性有显著性(P<0.05)。结论大剂量甲基强的松龙联合β-干扰素治疗MS急性期有效,能较快的促进神经功能的恢复,缩短病程。在降低复发率减轻残障程度和改善MRI病灶等方面,用皮下β-干扰素治疗多发性硬化疗效确切,不良反应小。     

Cyclophilin A affects Bcl-2 and Bax expression following beta-amyloid fragment 25-35-induced injury to PC12 cells★

BACKGROUND: Cyclophilin A can protect neurons against oxidative stress. OBJECTIVE: To investigate the effect of cyclophilin A on Bcl-2 and Bax protein expression in pheochro-mocytoma (PC12) cells treated with beta-amyloid fragment 25-35 (Aβ25-35), and to verify the protection pathway of cyclophilin A. DESIGN, TIME AND SETTING: The initial experiment was performed at the Laboratory of Department of Neurology, First Clinical College, China Medical University from November 2006 to July 2007. MATERIALS: PC12 cells were cultured at the Cell Center of Peking Union Medical College. Aβ25-35 (Sigma, USA), antibodies of Bcl-2 and Bax (Wuhan Boster, China), and recombinant human cyclophilin A (Biomol, USA) were used in this study. METHODS: PC12 cells were divided into three groups. Cells in the control group were incubated in culture medium. Cells in the Aβ25-35 injury group were incubated in medium containing a final concentration of 10 μmol/L of Aβ25-35. Cells in the cyclophilin A group were incubated in medium containing a final con-centration of 10 nmol/L of cyclophilin A for 30 minutes, and then treated with 10 μmol/L Aβ25-35. MAIN OUTCOME MEASURES: After 24 hours of culture, immunohistochemistry was used to detect Bcl-2 and Bax expression in PC12 cells. Annexin-V flow cytometry was employed to measure the apoptosis rate of PC12 cells. The MTT method was applied to examine the survival rate of PC12 cells. RESULTS: Bcl-2 expression decreased, whereas Bax expression increased in PC12 cells treated with Aβ25-35 (t = 2.277, 5.957, P < 0.05). However, in PC12 cells treated with Aβ25-35 and cyclophilin A, Bcl-2 expression increased and Bax expression decreased (t = 4.497, 2.531, P < 0.05). The survival rate of PC12 cells significantly decreased and the apoptosis rate increased (t=8.509, 22.886, P < 0.05) following Aβ25-35 treatment. Cyclophilin A enhanced the survival rate of PC12 cells to Aβ25-35-induced apoptosis (t = 4.895, 10.042, P < 0.05). CONCLUSION: Cyclophilin A can increase Bcl-2 expression and decrease Bax expression in PC12 cells treated with Aβ25-35, which indicates that cyclophilin A has a protective effect on Aβ25-35-induced injury to PC12 cells. Key Words: cyclophilin A; pheochromocytoma (PC12) cells; β-amyloid fragment 25-35; Bcl-2; Bax     

多发性硬化患者血清及脑脊液中干扰素-γ水平的研究

目的研究多发性硬化患者血清及CSF中干扰素-γ水平的变化,探讨干扰素-γ在MS发病中的作用。方法选择58例河北医科大学第二医院住院MS患者,临床表现符合Poser等制定标准的确诊(definite)或很可能(probable)MS诊断。选择40例无血缘关系的健康人,年龄、性别均与病例组匹配,近期无感染、未应用免疫抑制剂。血液及CSF标本应用双抗体夹心酶联免疫(ELISA)方法测定干扰素-γ含量。结果急性期MS组血清及脑脊液IFN-γ水平较正常对照组及缓解期MS组明显升高,且脑脊液INF-γ增高程度明显。结论 INF-γ水平在MS急性期增高,并随病情的缓解而逐渐恢复正常,说明INF-γ在MS发病过程中起促进作用。     

即刻和延迟治疗对新诊断癫痫患者复发的影响

目的 探讨不同治疗时机(即刻和延迟治疗)对新诊断癫痫患者复发的影响.方法 前瞻性收集新诊断癫痫患者的临床资料,根据治疗前发作次数将患者分为即刻治疗组(≤2次)及延迟治疗组(＞2次),给予合理抗癫痫药物治疗,至少观察2年.采用Kaplan-Meier统计分析比较2组患者治疗后至第1、2次复发的时间,同时比较治疗后不同随访时间点(3、6、12、24个月)的累计复发率.结果 共收集162例癫痫患者,其中即刻治疗组65例,延迟治疗组97例,随访2～14年(中位数3年).即刻治疗组治疗后至第1、2次复发时间均明显长于延迟治疗组,差异均有统计学意义(x2=5.94,P=0.020;x2=7.210,P=0.007).至随访终点,即刻治疗组有58.5%患者复发,低于延迟治疗组的72.2%,但差异没有统计学意义(x2=3.289,P=0.070).即刻治疗组和延迟治疗组治疗后3、6、12、24个月累计癫痫复发率分别为16.9%vs 35.1%、26.2%vs 48.5%、41.5%vs 56.7%、50.8%vs64.9%,仅在3、6月时差异均有统计学意义(x2=6.376,P=0.012;x2=8.098,P=0.004).结论 ≤2次癫痫发作后即刻给予合理抗癫痫药治疗可降低癫痫患者早期的复发风险.

Abstract：

Objective To explore the influences of immediate and deferred treatment with antiepileptic drugs (AEDs) on relapse of epilepsy in newly diagnosed patients. Methods The clinical data of newly diagnosed epileptic patients were collected prospectively and the patients were divided into immediate (seizures≤2) and deferred (seizures＞2) treatment groups according to times of seizures before treatment; these patients were treated with antiepileptic drugs reasonably. The patients were followed up for at least 2 years. Kaplan-Meier statistics was used to analyze the times to the first and second seizures after treatment. We also observed and compared their cumulative recurrence rate during the follow-up.Results One hundred and sixty-two patients were collected, 65 of which were in the immediate treatment group and 97 of which were in the deferred treatment group; The patients were followed up for 2-14 years(median 3 years). Times to the first and second seizures in the immediate treatment group were significantly longer than those in the deferred treatment group (x2=5.394, P=0.020; x2=7.210, P=0.007,respectively). Till the end of follow-up, 58.5% patients relapsed in the immediate treatment group, which was lower than that in the deferred treatment group (72.2%), but no statistical difference was noted (x2=3.289, P=0.07). The cumulative recurrence rates in the immediate and deferred treatment groups were 16.9% vs. 35.1% (x2=6.376, P=0.012), 26.2% vs. 48.5% (x2=8.098, P=0.004), 41.5% vs. 56.7% (x2=3.580,P=0.058) and 50.8% vs. 64.9% (x2=3.241, P=0.072) in the 3rd, 6th, 12th and 24th month of follow-up.Conclusion Immediate treatment with AEDs could reduce early recurrence rate of epilepsy in newly diagnosed epileptic patients with a few seizures (seizures ≤2).     

Cyclophilin A affects Bcl-2 and Bax expression following beta-amyloid fragment 25-35-induced injury to PC12 cells★

BACKGROUND: Cyclophilin A can protect neurons against oxidative stress.OBJECTIVE: To investigate the effect of cyclophilin A on Bcl-2 and Bax protein expression in pheochromocytoma (PCI2) cells treated with beta-amyloid fragment 25-35 (A β25-35), and to verify the protection pathway ofcyclophilin A.DESIGN, TIME AND SETTING: The initial experiment was performed at the Laboratory of Department of Neurology, First Clinical College, China Medical University from November 2006 to July 2007.MATERIALS: PCI2 cells were cultured at the Cell Center of Peking Union Medical College. A β25-35 (Sigma, USA), antibodies of Bcl-2 and Bax (Wuhan Boster, China), and recombinant human cyclophilin A (Biomol, USA) were used in this study.METHODS: PC12 cells were divided into three groups. Cells in the control group were incubated in culture medium. Cells in the Aβ25-35 injury group were incubated in medium containing a final concentration of 10 μ mol/L of Aβ25-35. Cells in the cyclophilin A group were incubated in medium containing a final concentration of 10 nmol/L of cyclophilin A for 30 minutes, and then treated with 10 μmol/L Aβ25-35. MAIN OUTCOME MEASURES: After 24 hours of culture, immunohistochemistry was used to detect Bcl-2 and Bax expression in PC12 cells. Annexin-V flow cytometry was employed to measure the apoptosis rate of PC12 cells. The MTT method was applied to examine the survival rate of PC12 cells.RESULTS: Bcl-2 expression decreased, whereas Bax expression increased in PCI2 cells treated with Aβ25-35 (t = 2.277, 5.957, P<0.05). However, in PC12 cells treated with Aβ25-35 and cyclophilin A, Bcl-2 expression increased and Bax expression decreased (t = 4.497, 2.531, P < 0.05). The survival rate of PC12 cells significantly decreased and the apoptosis rate increased (t=8.509, 22.886, P < 0.05) following Aβ25-35 treatment. Cyclophilin A enhanced the survival rate of PC12 cells to Aβ25-35-induced apoptosis (t = 4.895, 10.042, P< 0.05).CONCLUSION: Cyclophilin A can increase Bcl-2 expression and decrease Bax expression in PC12 cells treated with Aβ25-35, which indicates that cyclophilin A has a protective effect on Aβ25-35-induced injury to PC12 cells.     

激素联合β-干扰素治疗多发性硬化疗效分析

目的分析激素联合β-干扰素治疗多发性硬化的临床疗效。方法选择2012-01—2013-11我院诊治的63例多发性硬化患者,随机分为观察组和对照组。观察组33例采用激素联合β-干扰素治疗,对照组30例采用单纯激素治疗。比较2组治疗前后IFN-γ和IL-10浓度以及血清IL-6的变化,同时对2组伤残等级的疗效以及临床疗效作出评定。结果 2组治疗后IFN-γ浓度相比治疗前有明显降低,治疗后2组相比差异有统计学意义(t=74.5595,P0.05);治疗后IL-10浓度相比治疗前明显升高,2组治疗后相比差异有统计学意义(t=8.0886,P0.0001);2组治疗前后血清IL-6浓度比较差异均有统计学意义(P0.05);2组治疗后伤残等级平均评分差异有统计学意义(t=3.9341,P0.05);2组显效率比较差异有统计学意义(2χ=4.4978,P0.05)。结论激素联合β-干扰素治疗多发性硬化效果良好,值得临床推广。     

海上环境下海水浸泡复合型颅脑火器伤治疗的实验研究

目的 对海上环境下海水浸泡复合型颅脑火器伤提出有效的治疗方法,并探讨其治疗效果.方法 成年健康杂种犬60只制作成复合型颅脑火器伤动物模型,包括颅脑枪弹伤、胸腹部开放伤、四肢伤、烧伤,致伤后海水浸泡30min.按随机数字表法将其分为常规治疗组(对照组)和综合治疗组(治疗组),每组各30只.对照组采用常规治疗,治疗组在常规治疗的基础上加温低张液体、β-七叶皂甙钠、盐酸纳洛酮、左氧氟沙星和复温等综合治疗,并对两组动物进行经颅多普勒超声、动脉血气分析、血浆渗透压检测、颅内压监测和疗效比较.结果 治疗3 h后治疗组脑血管痉挛发生率低,经颅多普勒超声显示血流速度接近正常;12 h后治疗组血浆渗透压、代谢性酸中毒各项指标达到正常水平;24 h后治疗组颅内压明显下降.治疗组与对照组治疗后7 d动物存活率分别为70%和53%.治疗组各项指标都明显优于对照组,比较差异有统计学意义(P＜0.05).结论 早期温低张液体对复温、降低血浆透渗压、纠正电解质平衡、提高生存率有重要的意义,纳洛酮具有脑保护作用,β-七叶皂甙钠可减缓脑水肿的进程,降低颅内压和改善脑组织氧代谢;综合治疗对海水浸泡复合型颅脑火器伤具有显著疗效.

Abstract：

Objective To investigate the effective treatments of combined injury with craniocerebral firearm wound in dogs immersed by seawater under maritime environment. Methods Models of combined injury with craniocerebral firearm wound, including craniocerebral gunshot wound,open chest injury, open abdominal injury, open trauma of extremities and burn injury, were established in 60 healthy adult mongrel dogs. Animal models after being wounded were immersed by the seawater for 30 min, and then, they were equally randomized into conventional treatment group and comprehensive treatment group; 30 dogs in the conventional treatment group were given routine treatment and the other 30 dogs in the comprehensive treatment group were given lukewarm glucose liquid, β-aescin, naloxone hydrochloride, levofloxacin and re-warming treatments besides the conventional treatment. Transcranial Doppler ultrasound, blood gas analysis, measurement of plasma osmotic pressure and intracranial pressure (ICP) monitoring were performed on the dogs of the 2 groups; and the treatment efficacy of the 2groups were compared. Results Low incidence rate of brain vasospasm was noted and TCD indicated that blood flow speed approached normal in the comprehensive treatment group 3 h after the treatment.The plasma osmotic pressure and the indicators of metabolic acidosis reached normal levels in the comprehensive treatment group 12 h after the treatment. The ICP significantly decreased in the comprehensive treatment group 24 h after the treatment. Survival rate in the comprehensive treatment group (70%) was significantly higher as compared with that in the conventional treatment group (53%)7 d after the treatment (P＜0.05). All the indexes in the comprehensive treatment group were better than those in the conventional treatment group (P＜0.05) Conclusion Early infusion of lukewarm hypotonic solution can significantly reduce the osmotic pressure, correct the electrolyte balance, help the re-warming and prolong the survival rate. Naloxone possesses protective effect on brain. The β-aescine sodium can diminish viscosity, slow down brain edema progress, obviously reduce ICP and improve brain tissue oxygen metabolism. In a word, comprehensive treatment in effective in treating combined injury with craniocerebral firearm wound.     

β3—1a干扰素治疗多发性硬化症的临床观察

目的 探讨β-1a干扰索治疗多发性硬化症的临床疗效与安全性。方法 54例入选病例随机分为β-1a干扰素治疗组或安慰剂组，治疗组每次皮下注射β-1a干扰素20mg，每周3次，维持2年。用药患者在最初6个月中每月作1次神经系统检查，之后每3个月查1次。所有病人每年做2次MRI检查，并对所获数据进行统计学分析。结果 β-1a干扰素治疗的病人第1年和第2年的复发率比安慰剂组有明显降低（治疗组平均每人1．62次，安慰剂组2．78次）；复发危险性减低27％；首次复发时间推迟3个月（20mg组），并且无复发的病人比例大大提高（P〈0．05）。治疗组病人注射部位的局部反应很常见，但大多轻微。结论 在降低复发率、减轻残障程度和改善MRI病灶等方面，用皮下β-1a干扰素治疗多发性硬化疗效确切，不良反应小。     

Ratanasampil reduced levels of Aβ1-40 and Aβ1-42 and Aβ42/Aβ40 ratio in brains of Tg2576 mouse model of Alzheimer's disease

Objective To investigate the effect of ratanasampil (RNSP) which is traditional Chinese Tibet-Medicines on the β-amyloid peptide as a therapeutic target in Alzheimer's disease.Methods Thirteen female mice of 13-14 months old with Tg2576 transgene and ten BL6 × SJL mice as control were used in drug test All mice sacrificed after 8 weeks of RNSP treatment at 15-16 months of age.Open field activity and Y-maze tests were performed for animal behavioral change and memory ability.The β-amyloid peptides (Aβ1-40 and Aβ1-42) and β-amyloid precursor protein (APP) in Tg2576 mice brain were measured with western blot and enzyme linked immunosorbent assay (ELISA).Immunostaining with 1 E8 ( 1: 25 ) was carried out on brain sections of RNSP and vehicle-treated mice.Results The training times of Y-maze test decreased in RNSP-treated Tg2576 mice (P ＜0.01 ).After 2 months of RNSP treatment, a decrease in open field behavior was seen in Tg2576 mice ( P ＜ 0.05 ).The level of Aβ1-40 and Aβ1-42 in the brain was significantly decreased after RNSP treatment ( P ＜ 0.05 ).The Aβ42/Aβ40 ratio was significantly decreased after RNSP treatment as compared to vehicle-treated mice ( P ＜ 0.05 ) .But levels of APP in brain unchanged.Preliminary plaque counting of the sections showed reduced plaque numbers in the drug-treated mice in brain.Conclusions These results suggest that ratanasampil may reduce β-amyloid peptide production in brain to improve the learning and memory ability of Tg2576 mice of Alzheimer's disease.     

Ratanasampil reduced levels of Aβ1-40 and Aβ1-42 and Aβ42/Aβ40 ratio in brains of Tg2576 mouse model of Alzheimer's disease

Objective To investigate the effect of ratanasampil (RNSP) which is traditional Chinese Tibet-Medicines on the β-amyloid peptide as a therapeutic target in Alzheimer's disease.Methods Thirteen female mice of 13-14 months old with Tg2576 transgene and ten BL6 × SJL mice as control were used in drug test All mice sacrificed after 8 weeks of RNSP treatment at 15-16 months of age.Open field activity and Y-maze tests were performed for animal behavioral change and memory ability.The β-amyloid peptides (Aβ1-40 and Aβ1-42) and β-amyloid precursor protein (APP) in Tg2576 mice brain were measured with western blot and enzyme linked immunosorbent assay (ELISA).Immunostaining with 1 E8 ( 1: 25 ) was carried out on brain sections of RNSP and vehicle-treated mice.Results The training times of Y-maze test decreased in RNSP-treated Tg2576 mice (P ＜0.01 ).After 2 months of RNSP treatment, a decrease in open field behavior was seen in Tg2576 mice ( P ＜ 0.05 ).The level of Aβ1-40 and Aβ1-42 in the brain was significantly decreased after RNSP treatment ( P ＜ 0.05 ).The Aβ42/Aβ40 ratio was significantly decreased after RNSP treatment as compared to vehicle-treated mice ( P ＜ 0.05 ) .But levels of APP in brain unchanged.Preliminary plaque counting of the sections showed reduced plaque numbers in the drug-treated mice in brain.Conclusions These results suggest that ratanasampil may reduce β-amyloid peptide production in brain to improve the learning and memory ability of Tg2576 mice of Alzheimer's disease.     

夹闭术与血管内治疗破裂性宽颈动脉瘤的比较

目的 回顾性分析破裂性宽颈动脉瘤夹闭术及血管内治疗的疗效.方法 确诊的143例破裂性宽颈动脉瘤患者分别采用夹闭术(83例)和血管内治疗(60例),对两组患者并发症发生率、复发率及出院后6个月改良Rankin评分进行比较.结果 两组的并发症发生率、复发率及改良Rankin评分差异有统计学意义(P＜0.05),血管内治疗组较夹闭术组复发率高,但并发症少,患者预后好.结论 血管内治疗破裂性宽颈动脉瘤安全、有效,患者有着更好的生存质量.

Abstract：

Objective To analyze the clinical efficacy of clipping and endovascular treatment for ruptured wide-necked aneurysm Methods 143 patients with ruptured wide- necked aneurysm were treated by clipping ( n =83) or endovascular treatment ( n =60). Their complication rates、recurrence rates and modified Rankin scale scores at six months after leaving hospital were evaluated. Results The complication rate in endovasular treatment group was less than that in clipping group( P ＜ 0.05) significantly. The recurrence rate in clipping group was less than that in endovasular treatment group( P ＜ 0. 05) significantly. The modified Rankin scale in endovasular embolization group was less than that in clipping group( P ＜ 0. 05) significantly. Higher recurrence rate and lower complication rate were observed in endovasular treatment group. Patients with endovascular treatment had better prognosis. Conclusion Endovascular treatment for ruptured wide - necked aneurysm is efficient and safe. Better quality of life could be achieved.     

干扰素α-2B对复发性不可全切除性恶性脑膜瘤的治疗

文献报导脑膜瘤的总复发率为19％,部分切除和经活检证实的不可全切除的脑膜瘤复发率较高,为29％～40％,有组织浸润性者如非典型和恶性脑膜瘤5年的复发率达到38％和78％,初次手术后的放疗对部分切除的脑膜瘤有延缓复发和减少复发率的作用,但对已有复发者收效甚微,立体定向放射外科常用于小型的、难接近的、残余的和复发的肿瘤抬疗,化疗对组织学为非典型和恶性的脑膜瘤作用很小,作者报导了用干扰素α-2B(INF-α-2B)治疗6例复发有浸润性脑膜瘤的治疗结果。     

INF-γ第三内含子区+3586位点基因多态性与多发性硬化相关性的研究

目的 研究干扰素-γ(interferon gamma,IFN-γ)第三内含子区+3586位点单核苷酸多态性与多发性硬化(multiple sclerosis,MS)易感性的相关性.方法 选取河北医科大学第二医院住院多发性硬化患者58例,正常对照40例,采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)的方法对INF-γ第三内含子+3586位点单核苷酸多态性进行分析,经统计学处理,研究其与多发性硬化易感性的相关性.结果 IFN-γ+3586位点MS组与健康对照组基因型分布的比较差异没有统计学意义(P＞0.05);MS组IFN-γ+3586位点A及G等位基因频率与健康对照组比较均没有统计学意义(P＞0.05).结论 IFN-γ第三内含子区+3586位点基因多态性与MS的遗传易感性不相关.